Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 1,211 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $36.55, for a total transaction of $44,262.05. Following the transaction, the vice president now owns 10,859 shares in the company, valued at approximately $396,896.45. The sale was disclosed in a filing with the SEC, which is available at this link.

Karleen Marie Oberton also recently made the following trade(s):

  • On Tuesday, November 8th, Karleen Marie Oberton sold 984 shares of Hologic stock. The shares were sold at an average price of $38.57, for a total transaction of $37,952.88.
  • On Monday, November 7th, Karleen Marie Oberton sold 522 shares of Hologic stock. The shares were sold at an average price of $38.53, for a total transaction of $20,112.66.
  • On Monday, October 10th, Karleen Marie Oberton sold 31,470 shares of Hologic stock. The shares were sold at an average price of $40.00, for a total transaction of $1,258,800.00.

Hologic Inc. (NASDAQ:HOLX) traded down 0.54% during midday trading on Friday, reaching $38.37. 191,710 shares of the company traded hands. The company’s 50-day moving average price is $37.94 and its 200 day moving average price is $36.63. Hologic Inc. has a 12 month low of $31.84 and a 12 month high of $41.66. The firm has a market capitalization of $10.65 billion, a PE ratio of 33.08 and a beta of 1.13.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. The firm had revenue of $726.80 million for the quarter, compared to analyst estimates of $721.52 million. Hologic had a return on equity of 26.76% and a net margin of 11.68%. Hologic’s revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 earnings per share. On average, equities analysts anticipate that Hologic Inc. will post $2.15 earnings per share for the current year.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Institutional investors have recently added to or reduced their stakes in the stock. Thompson Siegel & Walmsley LLC raised its position in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the period. Norinchukin Bank The raised its position in Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares during the period. US Bancorp DE raised its position in Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares during the period. Calvert Investment Management Inc. raised its stake in shares of Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares during the last quarter. Finally, First Citizens Bank & Trust Co. raised its stake in shares of Hologic by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 10,559 shares of the company’s stock worth $410,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 96.42% of the company’s stock.

A number of research analysts have issued reports on HOLX shares. Piper Jaffray Cos. set a $40.00 price target on shares of Hologic and gave the company a “hold” rating in a research note on Monday, July 25th. They noted that the move was a valuation call. Evercore ISI raised shares of Hologic from a “hold” rating to a “buy” rating and upped their price objective for the company from $38.00 to $42.00 in a report on Thursday, July 28th. Jefferies Group upped their price objective on shares of Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Morgan Stanley upped their price objective on shares of Hologic from $38.00 to $40.00 and gave the company an “equal weight” rating in a report on Thursday, July 28th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Hologic in a report on Thursday, July 28th. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $43.20.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.